| Name | Title | Contact Details |
|---|---|---|
Kim Tripodo |
Executive Director and Head of Human Resources | Profile |
Earl Major |
Vice President, People and Culture | Profile |
We are a clinical-stage biopharmaceutical company focused on discovering and developing best-in-class therapies for patients with liver and gastrointestinal, or GI, diseases. Since our founding in 2014, we have invested in building a foundation of chemistry and biology expertise to drive innovative drug discovery and development. We believe these internal capabilities allow us to gain insights into disease targets and mechanisms and more quickly and purposefully design therapies with characteristics that we view as key to safety and efficacy. With this systematic approach, we have designed novel, proprietary farnesoid X receptor (FXR) clinical product candidates arising from a unique chemical scaffold with the potential to be best-in-class for non-alcoholic steatohepatitis, or NASH, and first- in-class for Inflammatory Bowel Disease, or IBD. In addition to our FXR program, we have continued to invest in drug discovery on other therapeutic targets that have effects on inflammation and/or fibrosis for which we believe we could develop proprietary small molecule therapies.
Los Angeles-based Capricor is a privately held biotechnology company that aims to create powerful, yet easy-to-administer cardiac stem cell treatments to regenerate damaged heart muscle and improve heart function for patients having suffered a heart attack.
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases.
DNA Diagnostics Center is a Fairfield, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Strateos is a pioneer in the development of remote access laboratories and lab control software for life science discovery.